PCM
ANAC

Prelude Capital Management’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Prelude Capital Management’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-300
Closed -$23K – 2128
2015
Q2 		$23K Buy
+300
New +$19.7K ﹤0.01% 1334
2015
Q1 		– Sell
-6,665
Closed -$215K – 2472
2014
Q4 		$215K Buy
6,665
+5,605
+529% +$168K 0.03% 613
2014
Q3 		$26K Buy
+1,060
New +$21.5K ﹤0.01% 1688

Other funds holding ANAC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM

Prelude Capital Management's ANAC Position: Q3 2015 in Review

Prelude Capital Management sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q3 2015, closing a stake of 300 shares — an estimated $23K sold.

Prelude Capital Management first reported a position in ANAC in Q3 2014 and held it in 3 quarters. The position peaked at $215K in Q4 2014. 213 funds tracked by Wall St. Rank hold ANAC as of Q3 2015.

  • Prelude Capital Management reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q3 2015 after selling out during the quarter.
  • Prelude Capital Management sold 300 ANACOR PHARMACEUTICALS INC COM shares in Q3 2015, an estimated $23K.
  • Prelude Capital Management first reported a position in ANACOR PHARMACEUTICALS INC COM in Q3 2014 and held it in 3 quarters.
  • Prelude Capital Management's ANACOR PHARMACEUTICALS INC COM position peaked at $215K in Q4 2014.
  • 213 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q3 2015.

Based on Prelude Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.